- Home
- SILC vs XBIT Comparison
SILC vs XBIT Comparison
Compare SILC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | XBIT |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.3M | 73.2M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SILC | XBIT |
|---|---|---|
| Price | $19.10 | $2.38 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 81.6K | 44.3K |
| Earning Date | 01-29-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,926,000.00 | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.56 | N/A |
| 52 Week Low | $12.44 | $2.09 |
| 52 Week High | $23.00 | $3.62 |
Technical Indicators
Market Signals| Indicator | SILC | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 42.83 |
| Support Level | $19.10 | $2.30 |
| Resistance Level | $21.22 | $2.45 |
| Average True Range (ATR) | 1.91 | 0.10 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 46.61 | 17.79 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.